Group items tagged

This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.

This notice announces the opportunity to apply for funding under the Rural Communities Opioid Response Program - Rural Centers of Excellence on Substance Use Disorders (RCORP-RCOE). RCORP-RCOE is part of the RCORP initiative, which is a multiyear effort to reduce the morbidity and mortality of substance use disorder (SUD), including opioid use disorder (OUD), in rural communities at the highest risk for these conditions. RCORP-RCOE will provide up to three years of funding to support three Rural Centers of Excellence (Centers) on SUD. The purpose of RCORP-RCOE is to support the identification, translation, dissemination, and implementation of evidence-based programs and best practices "related to the treatment for and prevention of substance use disorders within rural communities, with a focus on the current opioid crisis and developing methods to address future substance use disorder epidemics."1 The Centers will engage in research to identify "science-based prevention, treatment, and other risk reduction interventions, including community-based approaches that may be replicable in other rural communities and associated professional training."2 After identifying rural-relevant interventions, the Centers will serve as a resource for "scientific and technical assistance to county and state health departments and other entities as identified seeking guidance on how to address the substance use disorder challenges in their community."

NIDILRR proposes to fund two Disability and Rehabilitation Research Projects of three years each to conduct research on opioid use disorder among people with disabilities. Each grant will be funded up to $500,000. Topic of interest include: 1) Systematic review of existing literature on opioid-use disorder and people with disabilities; 2) Prevalence estimates and patterns of opioid use disorder treatment for people with disabilities; 3) Factors associated with increased risk for opioid use disorder; 4) Factors associated with improved access to treatment for opioid use disorder; 5) Interventions that contribute to improved outcomes; and 6) Effects of government policies and programs on access to treatment for people with disabilities who have opioid-use disorders.

The purpose of this program is to provide funding to states to enhance/expand their treatment service systems to increase capacity and provide accessible, effective, comprehensive, coordinated care, and evidence-based medication assisted treatment (MAT) and recovery support services to individuals with opioid use disorders seeking or receiving MAT. As a result of this program, SAMHSA seeks to: 1) increase the number of individuals receiving MAT services with pharmacotherapies approved by the FDA for the treatment of opioid use disorders; 2) increase the number of individuals receiving integrated care; and 3) decrease illicit drug use at 6-months follow-up. For the purpose of this RFA, integrated care is defined as the organized delivery and/or coordination of medical, behavioral or social and recovery support services provided to individual patients in order to produce better overall health outcomes for people that may have multiple healthcare needs. MAT is defined as the use of FDA-approved opioid agonist medications (e.g., methadone, buprenorphine products including buprenorphine/naloxone combination formulations and buprenorphine mono-product formulations) for the maintenance treatment of opioid use disorder and opioid antagonist medication (e.g., naltrexone products including extended-release and oral formulations) to prevent relapse to opioid use. MAT includes screening, assessment (which includes determination of severity of opioid use disorder, including presence of physical dependence and appropriateness for MAT) and case management. MAT is to be provided in combination with comprehensive substance use disorder treatment, including but not limited to: counseling, behavioral therapies and when needed pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically driven, person-centered and individualized setting. Priority will be given to states (listed in Appendix V) that have not only demonstrated a high rate of primary treatme

The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.

Established in 2009, the Hilda and Preston Davis Foundation was created to "...to advance the development of all areas of the lives of children and young adults…with special emphasis…on those suffering from eating disorders." The primary goal of The Hilda and Preston Davis Foundation Awards Program for Eating Disorders Research is to support innovative, clinically relevant research that seeks to understand the underlying biology of eating disorders, including anorexia nervosa and bulimia nervosa, leading to improved patient care. To meet this goal, the Program provides vital support to Senior Postdoctoral Fellows and Junior Faculty Investigators working in non-profit academic, medical and research institutions in the United States to build a strong workforce dedicated to the etiology of eating disorders, its associated pathologies, and to drive therapeutic and treatment development.

Blood disorders are causes of morbidity and mortality, affecting one in 76 people in the United States (US). Hemophilia, von Willebrand disease (VWD), venous thromboembolism (VTE), and thalassemia are the blood disorders addressed within three separate components in this notice of funding opportunity (NOFO). The purpose of this NOFO is to provide credible health information and evidence-based training as well as to support the implementation and evaluation of evidence-based health promotion and education programs. The health promotion framework will be used to ensure early identification, intervention, and management to improve outcomes for people with blood disorders. Applicants would apply to only one of the three following blood disorder components: 1) Hemophilia and VWD or 2) VTE or 3) Thalassemia.

Established in 2009, the Hilda and Preston Davis Foundation was created to "...to advance the development of all areas of the lives of children and young adults…with special emphasis…on those suffering from eating disorders." The primary goal of The Hilda and Preston Davis Foundation Awards Program for Eating Disorders Research is to support innovative, clinically relevant research that seeks to understand the underlying biology of eating disorders, including anorexia nervosa and bulimia nervosa, leading to improved patient care. To meet this goal, the Program provides vital support to Junior Faculty Investigators and Senior Postdoctoral Fellows working in non-profit academic, medical and research institutions in the United States to build a strong workforce dedicated to the etiology of eating disorders, its associated pathologies, and to drive therapeutic and treatment development. Applicants at the Senior Postdoc level should refer to the Guidelines for Senior Postdoctoral Fellows.

CHADD (Children and Adults with Attention Deficit Disorder) is now taking applications for its Young Scientist Research Fund Awards, a program to recognize new researchers making contributions to the understanding of ADHD.  CHADD will support two ADHD researchers with: ~ an unrestricted cash award of $5,000 each; ~ recognition at CHADD's Annual International Conference on ADHD ~ an allowance to cover most Conference-related expenses ~ a one-year CHADD professional membership. Applicants must be in the process of completing a doctoral degree or have completed one within the last three years with the doctoral degree awarded no earlier than January 2010. They must be involved in conducting research addressing an area of ADHD that will further understanding of the disorder. The research may address any area relevant to ADHD, including, but not limited to: ~ biological/genetic underpinnings of the disorder ~ treatment efficacy ~ impact on the individual or family ~ school or workplace accommodations ~ social stigma and discrimination ~ public health ~ epidemiology

The Substance Abuse and Mental Health Services Administration's (SAMHSA's) Center for Substance Abuse Treatment (CSAT) and Center for Mental Health Services (CMHS) are accepting applications for fiscal year (FY) 2015 Cooperative Agreements to Benefit Homeless Individuals for States (CABHI-States) grants. The purpose of this jointly funded program is to enhance or develop the infrastructure of states and their treatment service systems to increase capacity and provide accessible, effective, comprehensive, coordinated/integrated, and evidence-based treatment services; permanent supportive housing; peer supports; and other recovery support services to: * Individuals who experience chronic homelessness and have substance use disorders, serious mental illnesses (SMI), or co-occurring mental and substance use disorders; and/or * Veterans who experience homelessness/chronic homelessness and have substance use disorders, SMI, or co-occurring mental and substance use disorders. As a result of this program, SAMHSA seeks to: 1) improve statewide strategies to address planning, coordination, and integration of behavioral health and primary care services, and permanent housing to reduce homelessness; 2) increase the number of individuals, residing in permanent housing, who receive behavioral health treatment and recovery support services; and 3) increase the number of individuals placed in permanent housing and enrolled in Medicaid and other mainstream benefits (e.g., Supplemental Security Income/Social Security Disability Insurance [SSI/SSDI], Temporary Assistance for Needy Families [TANF], Supplemental Nutrition Assistance Program [SNAP]).

This notice solicits applications for the Rural Communities Opioid Response Program- Planning (RCORP-Planning).  The purpose of RCORP-Planning is to support treatment for and prevention of substance use disorder, including opioid use disorder (OUD), in rural counties at the highest risk for substance use disorder. The overall goal of RCORP-Planning is to reduce the morbidity and mortality associated with opioid overdoses in high-risk rural communities by multi-sector consortiums (as defined in the  "Eligibility Information" section) planning to strengthen their organizational and infrastructural capacity to address one or more of the following focus areas at the community, county, state, and/or regional levels: Prevention:  reducing the occurrence of opioid use disorder among new and at-risk users, as well as fatal opioid-related overdoses, through activities such as community and provider education, and harm reduction measures including the strategic placement and use of overdose reversing devices, such as naloxone, and syringe services programs; (See page 20 for additional information) Treatment:  implementing or expanding access to evidence-based practices for opioid addiction/OUD treatment, such as medication-assisted treatment (MAT) including developing strategies to eliminate or reduce treatment costs to uninsured and underinsured patients; and Recovery:  expanding peer recovery and treatment options that help people start and stay in recovery. RCORP-Planning will support one (1) year of planning funding.

The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Mental Health Services (CMHS) is accepting applications for fiscal year (FY) 2018 Mental Health Awareness Training grants (Short Title: MHAT). The purpose of this program is to: (1) train individuals (e.g., school personnel, emergency first responders, law enforcement, veterans, armed services members and their families) to recognize the signs and symptoms of mental disorders, particularly serious mental illness (SMI) and/or serious emotional disturbance (SED); (2) establish linkages with school- and/or community-based mental health agencies to refer individuals with the signs or symptoms of mental illness to appropriate services; (3) train emergency services personnel, veterans, law enforcement, fire department personnel, and others to identify persons with a mental disorder and employ crisis de-escalation techniques; and (4) educate individuals about resources that are available in the community for individuals with a mental disorder. It is expected that this program will prepare and train others on how to appropriately and safely respond to individuals with mental disorders, particularly individuals with SMI and/or SED.

In recognition of International Overdose Awareness Day, the Charles Koch Foundation seeks to support research projects (e.g. papers, conferences, workshops, etc.) that explore innovative, community-based solutions that are targeted at destroying the root causes of substance abuse. To that end, we are actively soliciting proposals for projects to consider innovative solutions that seek to alleviate substance use disorders. We are especially interested in research that: - Addresses innovative ways to help individuals overcome substance use disorders, prevent drug overdoses, and increase the willingness of individuals to seek treatment for substance abuse. - Explores the root causes of addiction and substance use disorders as well as innovative means to prevent substance abuse by remedying these root causes. - Addresses the unintended consequences of current approaches to reduce drug overdoses and substance abuse. - Examines solutions that offer a proactive approach to fighting addiction rather than a reactive approach focusing on treatment and recovery. - Explores opportunities to reduce the stigma associated with substance use disorders and celebrate success in overcoming addiction and substance abuse.

Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health (NIMH) seeks applications to develop, sustain, enhance, and enrich a centralized national biorepository for genetic studies of psychiatric disorders for facilitation and acceleration of the scientific understanding of the genetic risk architecture underlying mental disorders. This effort is expected to involve a functionally integrated, multi-disciplinary team that will provide for open sharing of biosamples and data resources through a single, centralized, national resource to advance basic and translational research in the genetics of mental disorders.

Since the 1990s the congressional budget has included funds for the the Centers for Disease Control and Prevention (CDC) to reduce or prevent the complications of hemophilia and other congenital bleeding disorders. Since 1996 the CDC has funded the federal network of hemophilia treatment centers (HTCs) for the collection of data for the monitoring of health indicators of importance to persons with bleeding disorders. This data is used to measure rates of complications of bleeding disorders and monitor trends over time (including inhibitors and other issues of blood and treatment product safety); identify high risk populations for prevention programs; and identify issues that require research. The purpose of this FOA is to continue the surveillance for these conditions through the HTCs.

The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), is accepting applications for fiscal year (FY) 2018 Targeted Capacity Expansion Hispanic/Latino Center of Excellence for Substance Use Disorder Treatment and Recovery Program (Short Title: Hispanic/Latino COE). The purpose of this program is to provide support for a Hispanic/Latino Center of Excellence to develop and strengthen the specialized behavioral healthcare and primary healthcare workforce that provides substance use disorder (SUD) treatment and recovery support services to Hispanic/Latino populations. This is accomplished by accelerating the adoption and implementation of culturally appropriate, evidence-based and promising SUD treatment and recovery-oriented practices and services; heightening the awareness, knowledge, and skills of the workforce that addresses the needs of Hispanic/Latino communities with substance use or other co-occurring health disorders; and fostering regional and national alliances among culturally diverse practitioners, researchers, policy makers, funders, and the recovery community. The Hispanic/Latino COE recipient will work directly with SAMHSA and in collaboration with the FY 2017 Addiction Technology Transfer Center (ATTC) National Coordinating Center and the Regional ATTCs on activities aimed at improving the quality and effectiveness of treatment and recovery, as well as working directly with providers of clinical and recovery support services, and others that influence the delivery of services, to improve the quality of workforce training and service delivery to Hispanic/Latino communities.

The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Mental Health Services (CMHS), is accepting applications for fiscal year (FY) 2018 -Treatment for Individuals with Serious Mental Illness, Serious Emotional Disturbance or Co-Occurring Disorders Experiencing Homelessness (Short Title: Treatment for Individuals Experiencing Homelessness). The purpose of this program is to support the development and/or expansion of the local implementation of an infrastructure that integrates behavioral health treatment and recovery support services for individuals, youth, and families with a serious mental illness, serious emotional disturbance or co-occurring disorder (i.e., a serious mental illness [SMI] and substance use disorder [SUD] or a serious emotional disturbance [SED] and SUD who are experiencing homelessness. The goal of this program is to increase capacity and provide accessible, effective, comprehensive, coordinated, integrated, and evidence-based treatment services, peer support and other recovery support services, and linkages to sustainable permanent housing. To achieve this goal, SAMHSA will support three types of activities: (1) integrated behavioral health treatment and other recovery-oriented services; (2) efforts to engage and connect clients to enrollment resources for health insurance, Medicaid, and mainstream benefits (e.g. Supplemental Security Income (SSI)/Social Security Disability Insurance (SSDI), Temporary Assistance for Needy Families (TANF), Supplemental Nutrition Assistance Program (SNAP), etc.); and (3) coordination of housing and services that support sustainable permanent housing.

Since the 1990s the congressional budget has included funds for the the Centers for Disease Control and Prevention (CDC) to reduce or prevent the complications of hemophilia and other congenital bleeding disorders. Since 1996 the CDC has funded the federal network of hemophilia treatment centers (HTCs) for the collection of data for the monitoring of health indicators of importance to persons with bleeding disorders. This data is used to measure rates of complications of bleeding disorders and monitor trends over time (including inhibitors and other issues of blood and treatment product safety); identify high risk populations for prevention programs; and identify issues that require research. The purpose of this FOA is to continue the surveillance for these conditions through the HTCs.

This Funding Opportunity Announcement (FOA) encourages grant applications from institutions/organizations that propose to support research on behavioral treatment for alcohol use disorders; organizational, financial, and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; and phenomenon of recovery from alcohol use disorders.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments.